Related Experiment Video

Updated: Jun 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

Simon J Dovedi1, Barry R Davies

  • 1Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Cancer Metastasis Reviews
|December 10, 2009
PubMed

Insights

Urothelial cell carcinoma, a common and costly cancer, often recurs after standard treatments. New molecularly targeted therapies are needed due to limited success in clinical trials.

Area of Science:

  • Oncology
  • Urology

Background:

  • Urothelial cell carcinoma (UCC) is the fifth most common cancer globally.
  • Superficial UCC, comprising 70% of new cases, frequently recurs, necessitating long-term management.
  • Current intravesical therapies have significant side effects and limited efficacy in about 30% of patients.

Purpose of the Study:

  • To highlight the unmet need for novel therapeutic strategies in urothelial cell carcinoma.
  • To underscore the challenges and opportunities for molecularly targeted therapy in bladder cancer.

Main Methods:

  • Review of current treatment standards for urothelial cell carcinoma.
  • Analysis of clinical trial outcomes for molecularly targeted agents in bladder cancer.
  • Genetic characterization of bladder cancer.

Main Results:

  • Standard treatments for superficial UCC have high recurrence rates.
  • Intravesical therapies are ineffective in a significant patient subset.
  • Clinical trials of targeted agents in bladder cancer have yielded limited success compared to other cancers.

Conclusions:

  • Bladder cancer presents a significant challenge for molecularly targeted therapy.
  • There is a critical need for the development of novel, effective treatments for UCC.
  • Further research into targeted agents is warranted to improve patient outcomes.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...